The World Health Organization (WHO) has issued its first-ever guidelines aimed at developing child-focused dengue treatments. This initiative represents a major milestone in global efforts to improve care for children infected with dengue fever, a mosquito-borne viral disease that continues to pose a growing public health threat worldwide.
Address an urgent need
Dengue cases have increased sharply in recent years, especially in tropical and subtropical regions. Children remain among the most vulnerable groups, as they face a greater risk of serious diseases and complications. Despite the increasing burden of disease, there are currently no licensed treatments for dengue, leaving supportive care as the primary management approach.
To address this gap, the World Health Organization introduced the Pediatric Drug Optimization Process (PADO) for the treatment of dengue. The framework aims to direct research, investment and development efforts towards safe and effective treatments designed specifically for children.
Key priorities for research and development
The guidelines identify several priorities to accelerate the development of child-friendly dengue treatments. These include identifying promising drug candidates, improving pediatric-friendly formulations, and encouraging more investment in research.
According to the WHO press release, the recommendations are based on discussions held during the PADO meeting held by WHO in October 2025. The meeting brought together experts to evaluate current evidence and identify critical gaps in the treatment of dengue in children.
Strengthening the global response
The World Health Organization emphasized that children need treatments tailored to meet their specific needs. The organization also called for stronger collaboration between researchers, governments, pharmaceutical companies and funding agencies to accelerate progress.
Furthermore, the guidance highlights the importance of ensuring equitable access to dengue treatments in the future, particularly in low- and middle-income countries where the disease burden remains high.
Looking forward
By setting clear priorities for the development of medicines for dengue fever in children, WHO aims to accelerate the provision of effective treatments for children. These guidelines represent an important step toward reducing serious illness, preventing complications, and ultimately saving lives in dengue-affected communities around the world.
